Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.40 |
| ▸ | NOS3 | P29474 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25652145 | 0.84 | CYP2C9 (0.35) | NOS2NOS3MAPTCYP2C9AURKA | |
| SCHEMBL21558448 | 0.73 | SIRT3 (0.36) | MAPTCYP2C9LMNATSHR | |
| SCHEMBL25652164 | 0.72 | MAPT (0.33) | NOS2NOS3MAPTCYP2C9 | |
| SCHEMBL25652158 | 0.69 | NOS2 (0.42) | NOS2NOS3MAPTCYP2C9DHFR | |
| SCHEMBL25652159 | 0.69 | UHRF1 (0.40) | NOS2NOS3 | |
| SCHEMBL18868429 | 0.67 | CYP3A4 (0.44) | MAPTCYP2C9LMNATSHR | |
| SCHEMBL3294193 | 0.67 | NOS2 (0.50) | NOS2NOS3CYP2C9LMNA | |
| SCHEMBL21558314 | 0.67 | ADORA2A (0.34) | — | |
| SCHEMBL21558316 | 0.67 | ADORA2A (0.34) | — | |
| SCHEMBL21558287 | 0.67 | ADORA2A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | NICOYA THERAPEUTICS (SHANGHAI) CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | NICOYA THERAPEUTICS (SHANGHAI) CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | XDH, CYP11B2, DPYD | NOS2 1505/4885NOS3 1523/4885MAPT 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.